PMID- 9563879
OWN - NLM
STAT- MEDLINE
DCOM- 19980528
LR  - 20071115
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 4
IP  - 4
DP  - 1998 Apr
TI  - Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic 
      myelogenous leukemia patients: comparison with the frequency detected in cycling 
      cells of the bone marrow.
PG  - 861-7
AB  - Monitoring the frequency of the Philadelphia (Ph) chromosome in chronic 
      myelogenous leukemia (CML) is important in determining the effectiveness of 
      treatment for patients during therapy. This can be done with high resolution by 
      subjecting short-term bone marrow cultures (48 h) to 24 h of mitotic arrest 
      before harvest and detecting Ph-positive (Ph+) metaphases by fluorescence in situ 
      hybridization (FISH) in a procedure termed hypermetaphase FISH or HMF. Here, we 
      compared procedures for detecting Ph+ interphase cells (interphase FISH or 
      I-FISH) in peripheral blood polymorphonucleocytes (PMNs) with HMF results on the 
      bone marrow of the same 26 CML patients in different stages of remission. The 
      probes for I-FISH in these experiments were relatively large (200-300 kb) and 
      sufficiently resolved in PMNs so that 97.5% of the cells were scorable. The 
      correlation between the frequencies of Ph+ cells from the two different cell 
      sources was excellent (r = 0.983, P < 0.0001); however, there was a consistently 
      higher level of Ph+ cells observed in the cycling marrow cells than in the 
      peripheral blood PMNs. This was discussed in terms of current theories of 
      apoptosis in CML cells. The large number of PMNs analyzable by I-FISH 
      (approximately 500/patient in this study) provided sufficiently narrow 99% 
      confidence intervals to suggest the procedure as an effective and efficient 
      method for monitoring the frequency of Ph+ cells in CML patients undergoing 
      therapy. However, for detection and quantification of minimal residual disease, 
      HMF is preferable to I-FISH because of the much lower frequency of false-positive 
      readings with the former procedure.
FAU - Seong, D
AU  - Seong D
AD  - Department of Hematology, University of Texas M.D. Anderson Cancer Center, 
      Houston 77030, USA.
FAU - Thall, P
AU  - Thall P
FAU - Kantarjian, H M
AU  - Kantarjian HM
FAU - Talpaz, M
AU  - Talpaz M
FAU - Swantkowski, J
AU  - Swantkowski J
FAU - Xu, J
AU  - Xu J
FAU - Shen, Y
AU  - Shen Y
FAU - Glassman, A
AU  - Glassman A
FAU - Ramagli, L
AU  - Ramagli L
FAU - Siciliano, M J
AU  - Siciliano MJ
LA  - eng
GR  - CA16672/CA/NCI NIH HHS/United States
GR  - CA34936/CA/NCI NIH HHS/United States
GR  - CA49639/CA/NCI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bone Marrow Cells/physiology
MH  - Cell Cycle
MH  - Female
MH  - Genetic Markers
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase/genetics
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood/*genetics
MH  - Male
MH  - Metaphase/genetics
MH  - Middle Aged
MH  - *Philadelphia Chromosome
EDAT- 1998/05/14 00:00
MHDA- 1998/05/14 00:01
CRDT- 1998/05/14 00:00
PHST- 1998/05/14 00:00 [pubmed]
PHST- 1998/05/14 00:01 [medline]
PHST- 1998/05/14 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1998 Apr;4(4):861-7.